{"id":"W2099088585","doi":"10.1200/jco.2008.20.1293","title":"Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2189,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Pfizer Canada; Genentech; GlaxoSmithKline; American Society of Clinical Oncology; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Internal medicine; Hazard ratio; Discontinuation; Alpha interferon; Adverse effect; Clinical endpoint; Gastroenterology; Log-rank test; Progression-free survival; Oncology; Urology; Proportional hazards model; Randomized controlled trial; Confidence interval; Interferon; Overall survival; Immunology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}